CoLucid Pharmaceuticals, Inc.

Eli Lilly & Co. has its second US approval in migraine in a little over one year, as the US Food and Drug Administration okayed Reyvow (lasmiditan) for the acute treatment of migraine on 11 October.

The US review of Eli Lilly & Co. ’s lasmiditan new drug application (NDA) will be the first significant test of FDA's final guidance on development of acute treatments for migraine. Released in Febru

Lilly Research Laboratories 's galcanezumab moved into the lead in the treatment of cluster headaches with a calcitonin gene-related peptide (CGRP) inhibitor via Phase III data reported May 15, but an

Eli Lilly & Co. said on May 14 that it will pay $110m up front to buy AurKa Pharma Inc. in a deal that will bring the Aurora kinase inhibitor AK-01 back home to Lilly, which licensed the molecule t